Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: bupropion XL Clear all

Conditions: Depression
Interventions: Paroxetine, Bupropion; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 45
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more

Conditions: Depression, Suicidal Ideation
Interventions: Paroxetine CR for Major Depressive Episode, Bupropion XL for Major Depressive Episode; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence
Interventions: Smoking-cessation treatment; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Tucson, Arizona • Rancho Cucamonga, California • Tarzana, California + 9 more

Conditions: Alcohol Abuse
Interventions: Bupropion, Placebo Oral Tablet; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 44 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 542
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 335 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Bupropion XL; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Major Depressive Disorder
Interventions: Bupropion XL 300; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depression, Side Effects, Sexual Dysfunction, Apathy
Interventions: Wellbutrin XL; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depressive Disorder
Interventions: WellbutrinXL, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Methamphetamine Use Disorder
Interventions: Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL®, Placebo (PLB) Oral; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more

Conditions: Major Depressive Disorder
Interventions: escitalopram, bupropion extra long (XL), escitalopram + bupropion; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder
Interventions: Bupropion HCl; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 25 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 2
States / cities: Culver City, California • Glendale, California

Conditions: Roux en Y Gastric Bypass
Interventions: Bupropion SR and XL; Drug
Lead sponsor: North Dakota State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Current Smoker, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Interventions: Bupropion Hydrochloride, Laboratory Biomarker Analysis, Nicotine Replacement, Quality-of-Life Assessment, Questionnaire Administration, Varenicline; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Charleston, South Carolina

Conditions: Substance Abuse, Cocaine Dependence
Interventions: Placebo, Bupropion XL, Abstinence Initiation, Relapse Prevention; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Depression
Interventions: Escitalopram, Bupropion; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Methamphetamine-dependence, Methamphetamine Abuse
Interventions: extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more

Conditions: Meniere Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
Interventions: Lamotrigine and Bupropion, Placebo; Drug
Lead sponsor: Dent Neuroscience Research Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Amherst, New York

Conditions: Breast Cancer, Major Depressive Disorder
Interventions: bupropion extended release (Wellbutrin XL); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Binge Drinking
Interventions: Naltrexone, Bupropion; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 34 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

Sexual Functioning Study With Antidepressants

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

Smoking-Cessation and Stimulant Treatment (S-CAST)

Buproprion for Binge Drinking

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Connectivity Affecting the Antidepressant REsponse Study

Clinical Study of Generic and Brand Bupropion in Depression

Wellbutrin XL Effects on SSRIs Induced Changes

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Does Dual Therapy Hasten Antidepressant Response?

Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery

Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Lamotrigine and Bupropion for Meniere's Disease

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

An Open Label Trial of Bupropion and Naltrexone for Binge Drinking